Key result
Coronary microvascular dysfunction in patients with non-obstructive CAD was associated with a higher 12-month risk of adverse cardiovascular events (45.2% vs 8.6%; OR 2.42, 95% CI 1.26-5.85).
Why the study?
To assess the development of adverse cardiovascular events in patients with non-obstructive CAD and coronary microvascular dysfunction identified by dynamic myocardial SPECT compared with patients without CMD.
Does the presence of coronary microvascular dysfunction increase the risk of adverse cardiovascular events in patients with non-obstructive CAD?
Cohort (n=118)
Does the presence of coronary microvascular dysfunction increase the risk of adverse cardiovascular events in patients with non-obstructive CAD?
Odds Ratio: 2.42 (95% CI 1.26–5.85)
Absolute Event Rate: 45.2% vs 8.6%
p-value: p=<0.001
In patients with non-obstructive CAD, coronary microvascular dysfunction identified by dynamic SPECT is associated with a significantly higher risk of adverse cardiovascular events at 12 months.
CMD may flag higher event risk in non-obstructive CAD; leaves open whether targeted therapy alters outcomes.
Aim. To assess the development of adverse cardiovascular events in patients with non-obstructive coronary artery disease (CAD) and coronary microvascular dysfunction (CMD), identified by dynamic myocardial single-photon emission computed tomography (SPECT), during 12-month follow-up compared with patients without CMD. Material and methods. The study included 118 patients (70 men, mean age, 62,0 [58,0; 69,0] years) with preserved ejection fraction (62 [59; 64] %) and non-obstructive CAD. Serum levels of the N-terminal pro-brain natriuretic peptide were assessed at baseline by enzyme immunoassay. Coronary flow reserve (CFR) was assessed by dynamic SPECT. CFR ≤2 was a CMD marker. Results. Six patients discontinued participation in the study due to loss of contact with them, while the rest were divided into groups depending on CMD presence: group 1 included patients with CMD (CFR ≤2; n=42), and group 2 was the control group and included patients without CMD (CFR >2; n=70). Within 12-month follow-up, 25 patients reported adverse events. According to Kaplan-Meier analysis, the prevalence of adverse cardiovascular events was higher in patients with CMD (45,2%, n=19) than in patients without it (8,6%, n=6) (p<0,001). Multivariate regression analysis showed that the presence of CMD (odds ratio (OR), 2,42; 95% confidence interval (CI), 1,26-5,85; p<0,001) and diastolic dysfunction (OR, 3,27; 95% CI, 2,26-5,64; p<0,001) were independent predictors of poor outcomes. The combination of CMD with diastolic dysfunction more than 5 times increased the risk of adverse events (OR, 5,18; 95% CI, 3,61-11,84; p<0,001). Conclusion. We found that in patients with non-obstructive CAD, the presence of CMD, identified by dynamic myocardial SPECT, was associated with a higher risk of adverse cardiovascular events within 12-month follow-up period than in patients without CMD. At the same time, the combination of CMD with diastolic dysfunction more than 5 times increased the risk of adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Kopyeva et al. (2023) conducted a cohort in non-obstructive coronary artery disease (n=118). Coronary microvascular dysfunction (CMD) vs. Patients without CMD was evaluated on adverse cardiovascular events (OR 2.42, 95% CI 1.26-5.85, p=<0.001). Coronary microvascular dysfunction in patients with non-obstructive CAD was associated with a higher 12-month risk of adverse cardiovascular events (45.2% vs 8.6%; OR 2.42, 95% CI 1.26-5.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: